This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Press Releases

ISTH and EAHAD Announce Partnership on Educational Components of the ISTH Gene Therapy in Hemophilia

Wednesday, September 30, 2020   (0 Comments)
Share |

CHAPEL HILL, NC, USA, (October 1, 2020) – The International Society on Thrombosis and Haemostasis (ISTH) and the European Association for Haemophilia and Allied Disorders (EAHAD) have announced an educational partnership to collaborate on components of the ISTH Gene Therapy in Hemophilia Education Initiative.

Together, the ISTH and EAHAD will work with The France Foundation (TFF) to develop and distribute tailored educational materials for the primarily European hemophilia practice community, including: a survey for allied health professionals, train-the-trainer workshops, podcast episodes, an EAHAD 2021 conference briefing and other learning sessions.

These resources will be available through the ISTH Gene Therapy in Hemophilia Education Initiative website along with an extensive archive of other educational materials keeping healthcare professionals up to date on this developing treatment option. EAHAD will also promote the content on a dedicated section of its website.

“The ISTH Gene Therapy in Hemophilia Education Initiative seeks to continuously provide the latest updates on the rapidly evolving treatment options for hemophilia, and partnerships like this one between the ISTH and EAHAD are essential to developing relevant content and distributing the information to the widest audience,” said Flora Peyvandi, M.D., Ph.D., Co-Chair of the ISTH Gene Therapy for Hemophilia Steering Committee and current President of EAHAD. “Scientists and physicians around the world are being challenged to keep current with the latest scientific developments and clinical advancements, and these educational programs are critical to ensure they are ready to deliver the best patient care when treatments like gene therapy become available.”

To learn more and view educational resources visit genetherapy.isth.org.

 

 

About the ISTH
Founded in 1969, the ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and hemostasis (clotting and bleeding). ISTH is an international professional membership organization with more than 7,500 clinicians, researchers and educators working together to improve the lives of patients in more than 100 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, clinical guidance and practice guidelines, research activities, meetings and congresses, peer-reviewed publications, expert committees and World Thrombosis Day on October 13. Visit ISTH online at www.isth.org.

About EAHAD
The European Association for Haemophilia and Allied Disorders (EAHAD) is a multidisciplinary association of healthcare professionals who provide care for individuals with haemophilia and other rare bleeding disorders. Its members include haematologists, internists, paediatricians, nurses, physiotherapists, laboratory scientists and researchers from across Europe. Since its establishment in 2007, EAHAD has worked to improve the situation of people living with haemophilia and other bleeding disorders. One of the key missions of EAHAD is to ensure the provision of the highest quality of clinical care for people with bleeding disorders. For more information about EAHAD and its activities, please visit http://www.eahad.org.


Membership Management Software Powered by YourMembership  ::  Legal